Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18031743 | 0.81 | ACE (0.53) | ACELMNASMN1; SMN2ABCB11 | |
| SCHEMBL15158982 | 0.81 | ACE (0.53) | ACELMNASMN1; SMN2ABCB11 | |
| SCHEMBL20227445 | 0.80 | ACE (0.67) | ACELMNA | |
| SCHEMBL16624673 | 0.79 | ACE (0.56) | ACELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19645413 | 0.78 | ACE (0.69) | ACELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31721186 | 0.73 | ACE (0.63) | ACELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13930194 | 0.71 | ACE (0.52) | ACELMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23157166 | 0.71 | NPC1 (0.55) | SMN1; SMN2HPGDNPC1TDP1MAPT | |
| SCHEMBL23157184 | 0.71 | NPC1 (0.55) | SMN1; SMN2HPGDNPC1TDP1MAPT | |
| SCHEMBL26616529 | 0.70 | SMN1; SMN2 (0.58) | LMNASMN1; SMN2KMT2AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155347-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | NEONC TECHNOLOGIES INC | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155347-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PERILLYL ALCOHOL DERIVATIVES | PLIN3, PLIN1, PLIN5 | ACE 3411/4885LMNA 1820/4885SMN1; SMN2 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.